biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Sep 16, 2016 5:21pm

144 Views

Post# 25246941

RE:RE:RE:RE:RE:RE:RE:RE:Regardless - the idiot

,,,,,,,speaking of revisionary history,,,,,, you certainly posted around the ad hoc analysis on the RVX board after the Assure trial failure,,,,,I dont recall anything positive in your posts,,,

Speaking of uninformed posters, it's "post hoc", not "ad hoc". At the time, I posted factual information about RVX's post hoc analysis when everyone on the board was treating those analyses like they were part of the original study. I explained post hoc analyses, along with the risks and limitations, and how they can be useful. You clearly still don't understand any of it.

And of course, there is no revisionist history there.

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute